39.58
1.73 (4.57%)
| Penutupan Terdahulu | 37.85 |
| Buka | 37.91 |
| Jumlah Dagangan | 689,237 |
| Purata Dagangan (3B) | 723,634 |
| Modal Pasaran | 2,001,719,936 |
| Harga / Pendapatan (P/E TTM) | 146.59 |
| Harga / Pendapatan (P/E Ke hadapan) | 121.95 |
| Harga / Jualan (P/S) | 7.41 |
| Harga / Buku (P/B) | 5.69 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Keuntungan | 1.25% |
| Margin Operasi (TTM) | -24.32% |
| EPS Cair (TTM) | 0.050 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 2.60% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 52.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 33.72% |
| Nisbah Semasa (MRQ) | 5.01 |
| Aliran Tunai Operasi (OCF TTM) | 57.56 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -22.77 M |
| Pulangan Atas Aset (ROA TTM) | -0.45% |
| Pulangan Atas Ekuiti (ROE TTM) | 1.13% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Vericel Corporation | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | -4.0 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | -0.50 |
|
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.06% |
| % Dimiliki oleh Institusi | 107.99% |
| Julat 52 Minggu | ||
| Median | 50.00 (26.33%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Truist Securities | 10 Nov 2025 | 50.00 (26.33%) | Beli | 38.99 |
| 15 Oct 2025 | 41.00 (3.59%) | Beli | 33.59 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| HOPPER JONATHAN MARK | - | 37.65 | -1,652 | -62,198 |
| WOTTON PAUL K | - | 37.52 | -5,000 | -187,600 |
| Jumlah Keseluruhan Kuantiti Bersih | -6,652 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -249,798 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 37.56 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| WOTTON PAUL K | Pengarah | 03 Dec 2025 | Jual (-) | 2,500 | 37.39 | 93,475 |
| WOTTON PAUL K | Pengarah | 02 Dec 2025 | Jual (-) | 2,500 | 37.65 | 94,125 |
| HOPPER JONATHAN MARK | Pegawai | 02 Dec 2025 | Jual automatik (-) | 1,652 | 37.65 | 62,198 |
| HOPPER JONATHAN MARK | Pegawai | 02 Dec 2025 | Pelaksanaan pilihan | 1,652 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 14 Nov 2025 | Pengumuman | Vericel to Present at the Stephens Annual Investment Conference on Thursday, November 20, 2025 |
| 06 Nov 2025 | Pengumuman | Vericel Reports Third Quarter 2025 Financial Results |
| 23 Oct 2025 | Pengumuman | Vericel to Report Third-Quarter 2025 Financial Results on November 6, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |